NHLD 2.69    Updated: 04-28-2017 $NHLD Last Trade:

New Post Public Reply Private Reply Replies (0) Message Board
stockcharts
18
NHLD 2.69    Updated: 04-28-2017 $NHLD
Last Trade: 4/28/2017
Last 2.69   
Open 2.69
Previous Close 2.69
Day High / Low 2.70 / 2.69
Year High / Low 3.88 / 2.11
Volume 13,304
Projected Volume 13304 (83%)
# of Trades / Projected 18 / 18
Dividend / Yield - / 0.00%
Abnormal Activity NONE
Abnormal Volume NO
Gap GAP UP
Candle NEUTRAL
Volatility Today LOW
Volatility Yesterday LOW
Price Relativity
From 40 Day High 85%
From 80 Day High 85%
From 150 Day High 78%
From 40 Day Low 105%
From 80 Day Low 117%
From 150 Day Low 117%
Pivot Analysis
Price Pivot $ 2.69
Day Resistance 1 $ 2.70
Day Support 1 $ 2.69
Day Resistance 2 $ 2.70
Day Support 2 $ 2.68
Consolidations
Short Term YES
Medium Term YES
Long Term NO
Volume Indicators
20 Day Avg Vol 15,985
Today / 20 Day Avg Vol BELOW
150 Day Avg Vol 21,591
Today / 150 Day Avg Vol BELOW
Abnormal Volume NO
William Volume Accumulation bullish
Volume Price Trend bullish
Momentum Indicators
10 Day Trend bullish
40 Day Trend bearish
100 Day Trend bearish
Stochastics bearish
RSI bearish
MACD bearish
Moving Average Indictors
15 Day Trend bearish
45 Day Trend bearish
100 Day Trend bearish
Mid Term Moving Average Crossover NONE
Long Term Moving Average Crossover NONE
Volatility Indicators
Abnormal Activity Today? NONE
Volatility Index Today LOW
Volatility Index Yesterday LOW
10 Day Volatility DECREASING
20 Day Volatility DECREASING
40 Day Volatility INCREASING

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Halozyme's Upcoming Investment Presentation at Healthcare Conference

Updated Category News Views 280

Halozyme's Participation in Major Healthcare Conference Halozyme Therapeutics, Inc. (NASDAQ: HALO) is set to showcase its advancements at an important healthcare conference. Dr. Helen Torley, the president and CEO, will present and engage in investor meetings, highlighting the company's innovative approaches in the biopharmaceutical sector. Details of the Presentation The...

Continue Reading
Emerging Markets Surge Ahead with Historic Bond Sales Strategy

Updated Category News Views 241

Emerging Markets Adjust with Record Bond Sales Amid economic uncertainty, borrowers in developing regions are intensifying their efforts to navigate potential market turbulence, particularly due to significant fluctuations influenced by US economic conditions. Authorities and businesses have proactively begun securing funds through bond sales, reflecting a strategic move...

Continue Reading
Multi Ways Holdings Reflects on Fiscal Year 2024 Performance

Updated Category News Views 167

Multi Ways Holdings Limited Reports on Financial Results Multi Ways Holdings Limited (NYSE American: MWG), a prominent provider of heavy construction equipment, has recently shared its financial outcomes for the fiscal year 2024. With a focus on innovation and customer satisfaction in Singapore and neighboring regions, the company continues to adapt to the dynamic market...

Continue Reading
Neurocrine Adjusts Course Following Luvadaxistat Study Setback

Updated Category News Views 117

Neurocrine Biosciences Shifts Strategy After Luvadaxistat Trial Neurocrine Biosciences Inc. (NASDAQ: NBIX) has made revisions to its strategic approach following the outcomes of the ERUDITE phase two clinical trial involving luvadaxistat (NBI-1065844). This investigational treatment aimed at addressing cognitive impairment in schizophrenia did not achieve its primary...

Continue Reading
Rinnai America Leads Coalition Against DOE Water Heater Rule

Updated Category News Views 294

Rinnai America Takes Action Against DOE Regulations Rinnai America Corporation, a prominent manufacturer of noncondensing tankless water heaters, has joined forces with 21 state attorneys general and various business groups to challenge the recent final rule issued by the U.S. Department of Energy (DOE) concerning consumer tankless water heaters. This action follows a...

Continue Reading